In a 21-year-old man with erythropoietic protoporphyria and a chromosome-18 deletion, clinical condition improved after an afamelanotide implant.
In plain wordsIn one young man with EPP, his condition improved after an afamelanotide implant.
- Peptide
- Melanotan I (afamelanotide)
- Outcome
- Not applicableClinical condition after afamelanotide implant
- Study
n = 1
- Outcome group
- Skin and hair · Skin and wound
- Studied dose
- Dose not stated · implantAs given in this study (human).
Source sentences
The patient's clinical condition improved following the June 2022 afamelanotide implant procedure.
1 context sentence(design, population, supporting numbers)
In this case study, we describe a 21-year-old man with erythropoietic protoporphyria who sought medical attention in April 2022 for diffuse edema and erythema of the hands.